Identification of fluoxetine as a direct NLRP3 inhibitor to treat atrophic macular degeneration Medical Sciences

The atrophic form of age-related macular degeneration (dry AMD) affects nearly 200 million people worldwide. There is no Food and Drug Administration (FDA)-approved therapy for this disease, which is the leading cause of irreversible blindness among people over 50 y of age. Vision loss in dry AMD results from degeneration...
Source: Proceedings of the National Academy of Sciences - Category: Science Authors: Tags: Medical Sciences Biological Sciences Source Type: research

Related Links:

Basel, 24 January 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that The Lancet has published two papers highlighting one-year results from four pivotal phase III studies of faricimab, an investigational bispecific antibody, in neovascular or “wet” age-related macular degeneration (nAMD) and diabetic macular edema (DME). [1,2] All four studies – which enrolled more than 3,000 people in total – met their primary endpoints, showing that people treated with faricimab up to every four months achieved non-inferior vision gains compare d to aflibercept given every two months. Notably, about ha...
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
Breakthrough offers hope of restoration of sight to people suffering vision loss because of dry AMDAn 88-year-old woman has told of her joy at becoming the first patient in the UK to benefit from a groundbreaking bionic eye implant that enabled her to detect signals for the first time since going blind.The woman from Dagenham suffers from geographic atrophy. The condition is the most common form of dry age-related macular degeneration (AMD), which affects millions of people worldwide and can cause loss of sight.Continue reading...
Source: Guardian Unlimited Science - Category: Science Authors: Tags: Blindness and visual impairment Health Disability Society Medical research UK news Source Type: news
Conclusion Aqueous biomarkers could help identify patients with nvAMD who may not require or benefit from long-term treatment with anti-VEGF therapy.
Source: Journal of Clinical Investigation - Category: Biomedical Science Authors: Source Type: research
Journal of Innovative Optical Health Sciences, Ahead of Print. Age-related Macular Degeneration (AMD) and Diabetic Macular Edema (DME) are two common retinal diseases for elder people that may ultimately cause irreversible blindness. Timely and accurate diagnosis is essential for the treatment of these diseases. In recent years, computer-aided diagnosis (CAD) has been deeply  investigated and effectively used for rapid and early diagnosis. In this paper, we proposed a method of CAD using vision transformer to analyze optical coherence tomography (OCT) images and to automatically discriminate AMD, DME, a...
Source: Journal of Innovative Optical Health Sciences - Category: Biomedical Science Authors: Source Type: research
ConclusionsOphthalmologic screening for AMD is highly effective in reducing blindness but is not cost-effective, as demonstrated by a Markov model based on real-world evidence from Japan.
Source: Japanese Journal of Ophthalmology - Category: Opthalmology Source Type: research
This study aims to estimate the availability of anti-VEGF treatment for patients with AMD and DME and demand for intravitreal injections (IVI) in the Russian Federation.
Source: Value in Health - Category: International Medicine & Public Health Authors: Source Type: research
Purpose: To assess the impact of disease activity on clinical outcomes in a “real-world” cohort with neovascular age-related macular degeneration over 5 years. Methods: Data were obtained from the prospectively defined Fight Retinal Blindness! registry. Eyes were divided into tertiles based on the proportion of visits where choroidal neovascular lesion was active (low, moderate, and high) up until 5 years. Results: Data from 2,109 eyes were included. The adjusted mean (95% confidence interval) visual acuity change was −0.5 letters (−1.8 to 1.1), 1.8 letters (0.2 to 3.4), and &minus...
Source: RETINA - Category: Opthalmology Tags: Original Study Source Type: research
This study aims to understand the profile and care of patients wit...
Source: BMC Ophthalmology - Category: Opthalmology Authors: Tags: Research Source Type: research
Conclusion: In this study, for the first time, we proposed a method for developing a sustained-release intraocular implant, consisting of ranibizumab by the heating method. This method allows for the industrial production of ranibizumab by extrusion and eliminates the complications related to reservoir systems.PMID:34888210 | PMC:PMC8642803 | DOI:10.34172/apb.2021.072
Source: Adv Data - Category: Epidemiology Authors: Source Type: research
Free Radic Biol Med. 2021 Dec 4:S0891-5849(21)00848-0. doi: 10.1016/j.freeradbiomed.2021.11.040. Online ahead of print.ABSTRACTAge-related macular degeneration (AMD) is a leading cause of blindness characterized by degeneration of retina pigment epithelium (RPE) and photoreceptors in the macular region. Activation of the innate immune cGAS-STING signaling has been detected in RPE of dry AMD patients, but the regulatory basis is largely unexplored. Heterochromatin is a highly compact, transcription inert chromatin status. We have recently shown that heterochromatin is required for RPE survival through epigenetically silenci...
Source: Free Radical Biology and Medicine - Category: Biology Authors: Source Type: research
More News: Academies | Age-Related Macular Degeneration (AMD) | Blindness | Eyes | Fluoxetine | Food and Drug Administration (FDA) | Opthalmology | Prozac | Science